First Manhattan Ups Vivus Proxy Ante By Proposing Zook As CEO
This article was originally published in The Pink Sheet Daily
Vivus’ largest shareholder, First Manhattan Co., said former AstraZeneca commercial head Tony Zook has agreed to serve as CEO of the obesity drug developer if shareholders vote for FMC’s board nominees July 15.
You may also be interested in...
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.